MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:MNKD
- CUSIP: 56400P20
- Web: www.mannkindcorp.com
- Market Cap: $153.53 million
- Outstanding Shares: 101,006,000
- 50 Day Moving Avg: $1.12
- 200 Day Moving Avg: $0.96
- 52 Week Range: $0.41 - $2.38
Sales & Book Value:
- Trailing P/E Ratio: 1.07
- Foreward P/E Ratio: -1.90
- P/E Growth: -0.06
- Annual Revenue: $177.77 million
- Price / Sales: 0.86
- Book Value: ($2.08) per share
- Price / Book: -0.73
- EBIDTA: $65.91 million
- Return on Equity: -15.95%
- Return on Assets: 46.57%
- Debt-to-Equity Ratio: -0.62%
- Current Ratio: 0.46%
- Quick Ratio: 0.41%
- Average Volume: 3.51 million shs.
- Beta: 3.26
- Short Ratio: 16.2
Frequently Asked Questions for MannKind (NASDAQ:MNKD)
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.09) by $0.08. The business earned $3 million during the quarter, compared to the consensus estimate of $3.50 million. The business's quarterly revenue was up 2900.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.06) earnings per share. View MannKind's Earnings History.
Where is MannKind's stock going? Where will MannKind's stock price be in 2017?
3 equities research analysts have issued 1-year price targets for MannKind's stock. Their forecasts range from $0.15 to $1.00. On average, they expect MannKind's stock price to reach $0.66 in the next twelve months. View Analyst Ratings for MannKind.
Are investors shorting MannKind?
MannKind saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 23,909,169 shares, an increase of 11.5% from the April 28th total of 21,447,866 shares. Based on an average daily volume of 7,556,248 shares, the days-to-cover ratio is currently 3.2 days. Currently, 43.3% of the company's stock are sold short.
Who are some of MannKind's key competitors?
Some companies that are related to MannKind include Minerva Neurosciences (NERV), Edge Therapeutics (EDGE), Sinovac Biotech (SVA), Concert Pharmaceuticals (CNCE), Ignyta (RXDX), Novavax (NVAX), Dynavax Technologies (DVAX), XBiotech (XBIT), Veracyte (VCYT), Nabriva Therapeutics AG - (NBRV), SIGA Technologies (SIGA), Kamada Ltd (KMDA), Compugen (CGEN), Curis (CRIS), Akebia Therapeutics (AKBA), Cerus (CERS), Anavex Life Sciences Corp. (AVXL) and Idera Pharmaceuticals (IDRA).
Who are MannKind's key executives?
MannKind's management team includes the folowing people:
- Kent Kresa, Chairman of the Board
- Matthew Jonathan Pfeffer CPA., Chief Executive Officer, Chief Financial Officer, Director
- Rose Alinaya, Senior Vice President, Principal Accounting Officer
- Linda Adreveno, Senior Vice President - Human Resources
- Joseph Kocinsky, Chief Technology Officer, Corporate Vice President
- David B. Thomson Ph.D., J.D., Corporate Vice President, General Counsel, Corporate Secretary
- Michael E. Castagna Pharm.D., Corporate Vice President, Chief Commercial Officer
- Raymond W. Urbanski M.D., Ph.D., Corporate Vice President, Chief Medical Officer
- Stuart A. Tross Ph.D., Chief People Officer
- James Samuel Shannon M.D., Director
Who owns MannKind stock?
MannKind's stock is owned by a variety of of institutional and retail investors. Top institutional investors include
FLYNN JAMES E
(5.17%), Vanguard Group Inc. (3.10%), Morgan Stanley (0.57%), Harel Insurance Investments & Financial Services Ltd. (0.51%), Geode Capital Management LLC (0.50%) and Bank of New York Mellon Corp (0.29%). Company insiders that own MannKind stock include Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya. View Institutional Ownership Trends for MannKind.
Who sold MannKind stock? Who is selling MannKind stock?
MannKind's stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Harel Insurance Investments & Financial Services Ltd., Geode Capital Management LLC, Morgan Stanley, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC, Wells Fargo & Company MN and Teachers Advisors LLC. View Insider Buying and Selling for MannKind.
Who bought MannKind stock? Who is buying MannKind stock?
MannKind's stock was purchased by a variety of institutional investors in the last quarter, including KCG Holdings Inc.. Company insiders that have bought MannKind stock in the last two years include Matthew J Pfeffer, Michael Castagna and Rosabel Realica Alinaya. View Insider Buying and Selling for MannKind.
How do I buy MannKind stock?
Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MannKind's stock price today?
MarketBeat Community Rating for MannKind (NASDAQ MNKD)MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of MannKind stock can currently be purchased for approximately $1.52.
Earnings History for MannKind (NASDAQ:MNKD)Earnings History by Quarter for MannKind (NASDAQ:MNKD)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2017||Q1 2017||($0.09)||($0.17)||$3.50 million||$3.00 million||View||N/A|
|3/16/2017||Q4 2016||($0.20)||($0.19)||$6.00 million||$12.40 million||View||N/A|
|11/9/2016||Q3 2016||($0.06)||$0.26||$2.00 million||$162.35 million||View||Listen|
Earnings Estimates for MannKind (NASDAQ:MNKD)
Current Year EPS Consensus Estimate: $-0.87 EPS
Next Year EPS Consensus Estimate: $-0.80 EPS
Dividend History for MannKind (NASDAQ:MNKD)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for MannKind (NASDAQ:MNKD)
Insider Ownership Percentage: 0.94%Insider Trades by Quarter for MannKind (NASDAQ:MNKD)
Institutional Ownership Percentage: 19.71%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|1/3/2017||Matthew J Pfeffer||CEO||Buy||4,540||$0.54||$2,451.60|| |
|1/3/2017||Rosabel Realica Alinaya||SVP||Buy||9,043||$0.54||$4,883.22|| |
|8/26/2016||Michael Castagna||Insider||Buy||17,500||$0.78||$13,650.00|| |
|8/24/2016||Michael Castagna||Insider||Buy||15,000||$0.87||$13,050.00|| |
|8/23/2016||Michael Castagna||Insider||Buy||25,000||$0.94||$23,500.00|| |
|8/15/2016||Matthew J Pfeffer||CEO||Buy||25,000||$0.99||$24,750.00|| |
|8/12/2016||Michael Castagna||Insider||Buy||25,000||$1.00||$25,000.00|| |
|5/17/2016||Michael Castagna||Insider||Buy||50,000||$0.93||$46,500.00|| |
|4/24/2015||Hakan Edstrom||CEO||Sell||73,460||$4.83||$354,811.80|| |
|3/27/2015||Hakan Edstrom||CEO||Sell||73,460||$5.21||$382,726.60|| |
|2/10/2015||Hakan Edstrom||CEO||Sell||73,460||$7.75||$569,315.00|| |
|2/5/2015||David Thomson||VP||Sell||80,000||$7.00||$560,000.00|| |
|1/5/2015||Diane Palumbo||VP||Sell||188,999||$5.95||$1,124,544.05|| |
|11/24/2014||David Thomson||VP||Sell||118,114||$6.14||$725,219.96|| |
|10/3/2014||Juergen Martens||VP||Sell||63,800||$5.48||$349,624.00|| |
|8/27/2014||Juergen Martens||VP||Sell||417||$7.60||$3,169.20|| |
|8/7/2014||David Thomson||VP||Sell||30,000||$8.16||$244,800.00|| |
|7/21/2014||Juergen Martens||VP||Sell||26,458||$9.65||$255,319.70|| |
|7/15/2014||Diane Palumbo||VP||Sell||17,901||$10.01||$179,189.01|| |
|7/1/2014||Matthew J Pfeffer||CFO||Sell||20,000||$10.44||$208,800.00|| |
|6/30/2014||Hakan Edstrom||COO||Buy||1,692||$4.42||$7,478.64|| |
|6/27/2014||Juergen Martens||VP||Sell||25,417||$10.53||$267,641.01|| |
|6/26/2014||David Thomson||VP||Sell||30,000||$10.51||$315,300.00|| |
|6/20/2014||Juergen Martens||VP||Sell||1,458||$10.34||$15,075.72|| |
|6/16/2014||Diane Palumbo||VP||Sell||17,902||$10.59||$189,582.18|| |
|6/5/2014||Juergen Martens||VP||Sell||120,000||$11.00||$1,320,000.00|| |
|6/4/2014||David Thomson||VP||Sell||133,000||$9.95||$1,323,350.00|| |
|6/3/2014||Diane Palumbo||VP||Sell||52,957||$9.50||$503,091.50|| |
|5/23/2014||Juergen Martens||VP||Sell||25,000||$7.65||$191,250.00|| |
|5/19/2014||Juergen Martens||VP||Sell||76,899||$7.50||$576,742.50|| |
|5/15/2014||Diane Palumbo||VP||Sell||18,176||$7.06||$128,322.56|| |
|1/24/2014||Juergen Martens||VP||Sell||50,000||$5.56||$278,000.00|| |
|12/31/2013||Hakan Edstrom||COO||Buy||1,589||$4.53||$7,198.17|| |
|12/20/2013||Juergen Martens||VP||Sell||32,054||$5.00||$160,270.00|| |
|12/11/2013||David Thomson||VP||Sell||150,000||$5.00||$750,000.00|| |
|11/29/2013||Juergen Martens||VP||Sell||48,057||$5.01||$240,765.57|| |
|11/15/2013||Diane Palumbo||VP||Sell||25,000||$5.02||$125,500.00|| |
|8/28/2013||David Thomson||VP||Sell||19,204||$5.78||$110,999.12|| |
|8/26/2013||Juergen Martens||VP||Sell||20,000||$5.52||$110,400.00|| |
|8/1/2013||Matthew J Pfeffer||CFO||Sell||10,000||$8.00||$80,000.00|| |
|7/2/2013||Matthew J Pfeffer||CFO||Sell||10,000||$7.00||$70,000.00|| |
|6/30/2013||Diane Palumbo||VP||Buy||1,610||$1.96||$3,155.60|| |
|6/30/2013||Matthew J Pfeffer||CFO||Buy||7,448||$1.96||$14,598.08|| |
|6/3/2013||Diane Palumbo||VP||Sell||66,849||$7.50||$501,367.50|| |
|5/16/2013||Diane Palumbo||VP||Sell||26,829||$5.25||$140,852.25|| |
|5/15/2013||Matthew J Pfeffer||CFO||Sell||10,000||$5.00||$50,000.00|| |
|12/31/2012||Matthew J Pfeffer||CFO||Buy||1,056||$1.95||$2,059.20|| |
|12/21/2012||Alfred E Mann||Major Shareholder||Buy||40,000,000||$2.59||$103,600,000.00|| |
Headline Trends for MannKind (NASDAQ:MNKD)
Latest Headlines for MannKind (NASDAQ:MNKD)
MannKind (MNKD) Chart for Monday, May, 29, 2017